Latuda is NOT indicated for bipolar mania
Lurasidone (Latuda) is FDA-approved specifically for bipolar I depression, NOT for the treatment of manic episodes. 1
FDA-Approved Indications for Latuda
According to the official FDA labeling, lurasidone is indicated for:
- Schizophrenia in adults and adolescents (13-17 years)
- Bipolar I depression (depressive episodes) as monotherapy in adults and pediatric patients (10-17 years)
- Bipolar I depression as adjunctive therapy with lithium or valproate in adults
The FDA label explicitly states: "The efficacy of LATUDA in the treatment of mania associated with bipolar disorder has not been established." 1
FDA-Approved Medications for Acute Mania
For acute manic episodes in bipolar I disorder, the FDA-approved options include 2:
- Lithium (approved down to age 12 years)
- Aripiprazole
- Valproate
- Olanzapine
- Risperidone
- Quetiapine
- Ziprasidone
- Chlorpromazine (generally not first-line)
Critical Safety Concern: Risk of Manic Switch
Using lurasidone in patients with inadequate mood stabilization carries a documented risk of precipitating manic episodes. Multiple case reports demonstrate lurasidone-induced manic switches in both adults and adolescents with bipolar I disorder 3, 4, 5.
One case involved a 43-year-old man who developed full mania within 2 weeks of lurasidone initiation when his valproate level was subtherapeutic 3. Another case described a male adolescent who became manic with psychotic features just 5 days after adding lurasidone to his regimen 4.
The proposed mechanism involves lurasidone's effects on serotonergic synapse signaling pathways through targets including MAOB, HTR1A, HTR2A, HTR3A, SLC18A2, HTR1B, and HTR7 5.
Clinical Bottom Line
Do not use lurasidone for acute mania. It lacks efficacy data for this indication and carries a risk of worsening manic symptoms. For bipolar mania, initiate treatment with lithium, valproate, or an FDA-approved atypical antipsychotic (aripiprazole, olanzapine, risperidone, quetiapine, or ziprasidone) 2.
Reserve lurasidone exclusively for the depressive phase of bipolar I disorder, and ensure adequate mood stabilization is in place before initiating treatment to minimize the risk of treatment-emergent mania 6, 7.